Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6603437.pdf
Reference31 articles.
1. Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A, Fujita S (2001) Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 97: 2903–2907
2. Autexier C (1999) Telomerase as a possible target for anticancer therapy. Chem Biol 6: R299–R303
3. Boyton RJ, Altmann DM (2002) Is selection for TCR affinity a factor in cytokine polarization. Trends Immunol 23: 526–529
4. Brunsvig P, Dueland S, Moller M, Gjertsen MK, Trachsel S, Aamdal S, Gaudernack G (2006) Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother 15 (12): 1553–1564
5. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403–2413
Cited by 242 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms;Experimental Biology and Medicine;2024-01-31
2. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations;Frontiers in Cell and Developmental Biology;2023-11-15
3. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial;British Journal of Cancer;2023-10-30
4. Systemic treatment for advanced pancreatic cancer;World Journal of Gastrointestinal Oncology;2023-10-15
5. Combining old and new concepts in targeting telomerase for cancer therapy: transient, immediate, complete and combinatory attack (TICCA);Cancer Cell International;2023-09-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3